阿替利珠单抗治疗新诊断III/IV期卵巢癌的安慰剂对照随机III期IMagyn050/GOG 3015/ENGOT-OV39试验的总生存期与患者报告结局结果
该双盲随机III期试验将新诊断III/IV期卵巢癌患者分配至每3周阿替利珠单抗1200 mg或安慰剂联合铂类化疗和贝伐珠单抗治疗22个周期。中位随访38个月后,PD-L1阳性人群总生存风险比为0.83(95%CI 0.66-1.06;p=0.13),意向治疗人群为0.92(95%CI 0.78-1.09)。患者报告结局在两组间无差异。
要点
- PD-L1阳性人群总生存风险比0.83(95%CI 0.66-1.06;p=0.13),未达统计学显著。
- 意向治疗人群总生存风险比0.92(95%CI 0.78-1.09),中位总生存50.5个月对46.6个月。
- 第9周时两组腹痛腹胀、功能和健康相关生活质量改善比例相似,治疗相关症状无差异。
核心结论
- 将阿替利珠单抗加入新诊断卵巢癌标准治疗未显著改善疗效,也未给患者增加额外治疗负担。
研究设计与样本
- 安慰剂对照双盲随机III期IMagyn050/GOG 3015/ENGOT-OV39试验(NCT03038100)。
- 合格患者分配至每3周阿替利珠单抗1200 mg或安慰剂,共22个周期,联合铂类化疗和贝伐珠单抗。
- 共同主要终点为PD-L1阳性和意向治疗人群的无进展生存期(已报告)和总生存期,按层次检验。
- 预设患者报告结局分析聚焦疾病相关腹痛腹胀症状(EORTC QLQ-OV28)、功能和健康相关生活质量(QLQ-C30)。
主要发现
- 中位随访38个月后,PD-L1阳性人群总生存风险比0.83(95%CI 0.66-1.06;p=0.13);阿替利珠单抗组中位总生存不可估计,安慰剂组为49.2个月。
- 意向治疗人群总生存风险比0.92(95%CI 0.78-1.09),中位总生存阿替利珠单抗组50.5个月对安慰剂组46.6个月。
- 第9周时,新辅助队列两组中腹痛腹胀、功能和健康相关生活质量较基线改善≥10分的患者比例相似。
- 在初次手术队列中,两组随时间推移身体和角色功能及健康相关生活质量较基线改善、稳定或恶化的患者比例相似。
- 两个队列均未显示两组间治疗相关症状或总体副作用困扰的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the impact on overall survival (OS) and patient-reported outcomes (PROs) of combining atezolizumab with standard therapy for newly diagnosed stage III/IV ovarian cancer. METHODS: The placebo-controlled double-blind randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial (NCT03038100) assigned eligible patients to 3-weekly atezolizumab 1200 mg or placebo for 22 cycles with platinum-based chemotherapy and bevacizumab. Coprimary endpoints were progression-free survival (already reported) and OS in the PD-L1-positive and intent-to-treat (ITT) populations, tested hierarchically. Prespecified PRO analyses focused on disease-related abdominal pain and bloating symptoms (European Organisation for Research and Treatment of Cancer QLQ-OV28), functioning, and health-related quality of life (HRQoL) (QLQ-C30). RESULTS: After 38 months' median follow-up, the OS hazard ratio in the PD-L1-positive population was 0.83 (95% CI, 0.66-1.06; p = 0.13); median OS was not estimable with atezolizumab versus 49.2 months with placebo. The hazard ratio for OS in the ITT population was 0.92 (95% CI, 0.78-1.09; median 50.5 versus 46.6 months, respectively). At week 9, similar proportions of patients in both arms of the neoadjuvant cohort showed ≥10-point improvement from baseline in abdominal pain and bloating, functioning, and HRQoL. In the primary surgery cohort, similar proportions of patients in each arm had improved, stable, or worsened physical and role function and HRQoL from baseline over time. Neither cohort showed differences between arms in treatment-related symptoms or overall side-effect bother. CONCLUSIONS: Incorporation of atezolizumab into standard therapy for newly diagnosed ovarian cancer does not significantly improve efficacy or impose additional treatment burden for patients. CLINICALTRIALS: gov registration: NCT03038100.
引用
- Pignata S, Bookman M, Sehouli J, et al. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023. PMID: 37625235. doi:10.1016/j.ygyno.2023.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。